ライフサイエンスコーパス: drug allergy

1 tion of allergic patients (e.g., in food and drug allergy).

2 None correlated with history of drug allergy.

3 ms, diagnosis, management, and prevention of drug allergy.

4 Infectious Diseases sponsored a workshop on drug allergy.

5 o issue an International CONsensus (ICON) on drug allergy.

6 e of 0.02-0.4 g), and 4 of 368 patients with drug allergy.

7 allograft dysfunction such as infection and drug allergy.

8 esponses, including food, environmental, and drug allergies.

9 new concepts for treatment and prevention of drug allergies.

10 8; 95% CI, 1.4-16.4) and parental history of drug allergy (adjusted odds ratio = 3.0; 95% CI, 1.3-6.8

11 A drug allergy passport, a drug allergy alert card, a certificate, and a discharge

12 support quality management of patients with drug allergies and better facilitate healthcare planning

13 e aimed to describe the prevalence of common drug allergies and patient characteristics documented in

14 al disease, metabolic bone disease, cancers, drug allergies and toxic effects, and complications asso

15 n of patients with food-, insect venom-, and drug allergy and chronic urticaria.

16 actams are among the most frequent causes of drug allergy and constitute an important clinical proble

17 Thus, the European Network on Drug Allergy and Drug Allergy Interest Group of the Euro

18 The European Network on Drug Allergy and Drug Allergy Interest Group of the Euro

19 tial for precision medicine in food allergy, drug allergy, and anaphylaxis under the auspices of the

20 od allergy, atopic dermatitis, some forms of drug allergy, and insect sting allergy).

21 physiology and diagnosis of non-IgE-mediated drug allergy are offered, with novel data regarding the

22 y be allergic or nonallergic in nature, with drug allergies being immunologically mediated DHRs.

23 the 1250 outpatients referred for suspected drug allergy between July 2013 and June 2014 were evalua

24 n medicine approach to treatment of food and drug allergy, but further validation and quantification

25 ealth and Care Excellence (NICE) Guidance on Drug Allergy-CG183.

26 Drug allergy data were obtained from EHRs of patients wh

27 gy passport as well as general guidelines of drug allergy documentation.

28 The prevalence of drug allergies documented in electronic health records (

29 European Network on Drug Allergy/EAACI protocol was appropriate and safe whe

30 hylaxis, angioedema, asthma, conjunctivitis, drug allergies, eczema, food allergy, rhinitis, urticari

31 igated according to the European Network for Drug Allergy (ENDA) guidelines and patients found to be

32 European Network on Drug Allergy (ENDA) has proposed an algorithm for diagno

33 NSAIDs) proposed by the European Network for Drug Allergy (ENDA) interest group (2011) was revised in

34 nes were devised by the European Network for Drug Allergy (ENDA) on behalf of the European Academy of

35 uidelines for investigation of perioperative drug allergy exist, but the quality of services is unkno

36 The clinical allergy section focuses on drug allergy, food allergy and immunotherapy.

37 linical Immunology (EAACI) Interest Group on Drug Allergy has performed a literature search on skin t

38 The most commonly reported drug allergies in this population were to penicillins (1

39 Drug "allergies" in general, but most those notably to p

40 Advances in drug allergy include identification of HLA associations

41 The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of A

42 us, the European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of A

43 The diagnosis of drug allergy is often based on history alone, which is a

44 any evidence of immune activation in a mouse drug allergy model.

45 Penicillin is the most common drug "allergy" noted at hospital admission, although it

46 rrect diagnosis of other conditions, such as drug allergy or autoimmune disease.

47 sthma, definitions of endotypes for food and drug allergy or for anaphylaxis lag behind.

48 exceptions were clinical contraindications, drug allergies, or drug intolerances.

49 rtion of each allergy to the total number of drug allergies over time.

50 ogy have formed a task force and developed a drug allergy passport as well as general guidelines of d

51 A drug allergy passport should at least contain informatio

52 A drug allergy passport, a drug allergy alert card, a cert

53 eported drug allergy with an average of 1.95 drug allergies per patient.

54 In addition, food and drug allergies represent a neglected area of research in

55 rmacogenomics discussed the current state of drug allergy research.

56 quency of patients having 1, 2, 3..., or 10+ drug allergies was reported.

57 Drug allergies were most prevalent among females and whi

58 35.5% of patients had at least one reported drug allergy with an average of 1.95 drug allergies per

59 International experts in the field of drug allergy with backgrounds in allergy, immunology, in

60 4 [1.3-8.9], and with cANCA 3.3 [1.0-10.8]), drug allergy (with PSV 3.6 [1.8-7.0], with WG 4.0 [1.8-8

61 ast to patients who had undergone a complete drug allergy workup.